Apparently, we’ve discovered another longevity miracle. This time it’s Cialis.
A recent Verywell Health article reports that men taking tadalafil, the popular erectile dysfunction drug, have a 34 percent lower risk of death, a 27 percent lower risk of heart attack, a 34 percent lower risk of stroke, and a 32 percent lower risk of dementia. Impressive numbers. One might reasonably wonder why we’re not putting it in the drinking water.
There’s just one problem. No randomized trial has demonstrated that tadalafil prevents heart attacks, dementia, or death in otherwise healthy men taking it for longevity. And that distinction matters.
The problem with the magic numbers
The figures come from a study published in the American Journal of Medicine involving more than 500,000 men with erectile dysfunction. Researchers examined electronic health records and found that men prescribed tadalafil experienced fewer adverse cardiovascular events and deaths over three years.
Real physician voices, twice a week
Free, and one click to unsubscribe.
But the men weren’t randomly assigned to tadalafil or placebo. Researchers compared patients who received prescriptions with those who didn’t. That’s not a minor statistical technicality. It’s the difference between discovering that a medication works and discovering that people who take it are different from people who don’t.
Consider two sixty-five-year-old men with erectile dysfunction. One exercises regularly, sees his physician, remains sexually active, and feels well enough to seek treatment. The other has significant coronary disease, limited exercise tolerance, and takes nitrates for angina.
Guess which one is more likely to receive Cialis? And which one is more likely to be alive three years later?
The investigators used propensity-score matching to adjust for measured differences between patients. That’s helpful, but it cannot account for everything: physical fitness, frailty, sexual activity, health-seeking behavior, or the severity of underlying illness.
There’s another problem. Patients taking nitrates generally cannot receive tadalafil because the combination can cause dangerous hypotension. Some patients with substantial cardiovascular disease are therefore systematically less likely to receive the drug. Epidemiologists call this confounding by contraindication.
I call it a pretty good reason to be skeptical.
Where’s the absolute risk reduction?
We’re told the relative risk of death was 34 percent lower. But what does that mean for an individual patient? What were the actual event rates? What’s the absolute difference? And, most importantly, how much of that difference was caused by tadalafil?
The article doesn’t adequately answer these questions. Even if we knew the absolute difference between the groups, we couldn’t legitimately calculate a treatment number needed to treat (NNT) without establishing causality.
I’ve spent much of my career watching relative risk reductions presented as though they tell us everything we need to know about a drug. They don’t.
A 34 percent relative reduction might represent an enormous clinical benefit or a relatively small absolute difference. And in an observational study, it might not represent a drug benefit at all.
The dementia studies that complicate the story
The reported 32 percent reduction in dementia is particularly appealing. Who wouldn’t want a pill that improves erections and protects the brain? Unfortunately, other studies tell a less exciting story.
A study published online in 2024 in Neuroepidemiology compared 5,204 men starting daily low-dose tadalafil for benign prostatic hyperplasia with 18,565 men starting alpha-blockers. The result? Essentially no difference in dementia risk. Hazard ratio: 0.99 (95 percent confidence interval 0.88 to 1.12).
The same investigators examined another cohort of 133,336 men with erectile dysfunction. Again, no statistically significant protection: hazard ratio 0.95 (95 percent confidence interval 0.86 to 1.04).
A separate Medicare-based study published in Brain Communications in 2022 also failed to find convincing evidence that phosphodiesterase-5 (PDE5) inhibitors reduced Alzheimer’s disease or related dementia.
To be fair, not every study has been negative. A large 2024 study in Neurology reported an 18 percent lower risk of Alzheimer’s disease among men prescribed PDE5 inhibitors. But when investigators excluded the first three years of follow-up, the association weakened and was no longer statistically significant. That should make us wonder whether we’re observing a drug effect or simply identifying men who were healthier before they ever swallowed their first pill.
A 2025 Mendelian randomization study also found no evidence supporting a causal protective effect against Alzheimer’s disease, although that method has limitations of its own. The Verywell article acknowledges observational bias, to its credit. But the conflicting evidence deserves more attention than it receives.
A beautiful mechanism proves very little
Tadalafil inhibits phosphodiesterase-5, increasing cGMP signaling and promoting vascular relaxation. Researchers have proposed benefits involving endothelial function, blood flow, platelet activity, and oxidative stress.
All interesting. All biologically plausible. And none establishes that tadalafil extends life.
I’ve practiced medicine long enough to watch plenty of beautiful mechanisms collapse when someone finally conducts a randomized trial. Improving blood flow isn’t necessarily the same as preventing a heart attack. Improving a laboratory measurement isn’t necessarily the same as preventing a stroke.
A drug’s mechanism tells us why it might work. It doesn’t tell us whether it does.
But what about the cardiovascular studies?
A 2024 study in Clinical Cardiology reported 44 percent lower all-cause mortality among men exposed to tadalafil. Again, impressive.
But this was another observational analysis. Men with tadalafil prescription claims were compared with men without PDE5 inhibitor claims. Differences in baseline health, treatment selection, and exposure classification remain important concerns.
Interestingly, among men with established coronary artery disease, the mortality association wasn’t statistically significant. The hazard ratio was 1.40, although the confidence interval was wide (0.57 to 3.42), making the result inconclusive. That doesn’t demonstrate harm. It simply doesn’t establish protection.
A 2024 meta-analysis pooled sixteen studies and found associations between PDE5 inhibitor use and lower cardiovascular event rates and mortality. But fifteen of those studies were observational.
Pooling studies doesn’t eliminate the biases they share. Sometimes it just gives us a more precise estimate of the wrong answer.
So should we prescribe Cialis for longevity?
Not yet.
Tadalafil is an effective treatment for erectile dysfunction and urinary symptoms associated with benign prostatic hyperplasia. It also has an established role in pulmonary arterial hypertension. Those are legitimate reasons to prescribe it. Extending lifespan in otherwise healthy people is not an established indication.
The drug isn’t harmless. It can cause headache, flushing, back pain, hypotension, and potentially serious interactions with nitrates. Rare cases of sudden visual or hearing loss have also been reported, although causality remains uncertain.
When a medication treats a bothersome symptom, accepting some risk may be reasonable. When we’re treating healthy people for a benefit that hasn’t been demonstrated, the calculation changes.
I would love for tadalafil to prevent cardiovascular disease and dementia. It’s inexpensive, familiar, and physiologically interesting. The observational findings are worth investigating.
Unfortunately, large randomized outcomes trials are expensive, and generic drugs rarely attract enthusiastic commercial sponsors. But that doesn’t lower the standard of evidence.
The lesson we’re missing
There’s one genuinely important cardiovascular message buried in this story. Erectile dysfunction can be an early marker of vascular disease.
A middle-aged man presenting with new erectile dysfunction deserves a cardiovascular risk assessment, including blood pressure, lipids, glucose, smoking history, and an honest discussion about his vascular health. That may prove considerably more valuable than handing him a prescription and suggesting it will protect his arteries.
If tadalafil improves his sexual function, wonderful. That’s a meaningful benefit in its own right.
But let’s stop confusing an association with a demonstrated treatment effect. We’ve spent decades allowing relative risk reductions to substitute for absolute benefits. Now we’re increasingly allowing observational correlations to substitute for randomized evidence.
Perhaps tadalafil really does extend life. I hope it does. But hope isn’t evidence, and a statistically significant association isn’t a clinical trial.
Cialis may help men get more out of life. Whether it helps them get more life remains unproven. Until someone demonstrates otherwise, that’s the distinction worth keeping erect.
Larry Kaskel is an internist and self-described “lipidologist in recovery” who has practiced medicine for more than 35 years, with an emphasis on prevention, wellness, and longevity. He runs a concierge medical practice in the Chicago area and serves on the teaching faculty at Northwestern University Feinberg School of Medicine.
He is the former host of Lipid Luminations on ReachMD and author of Dr. Kaskel’s Living in Wellness. His writing frequently challenges conventional medical wisdom and explores new approaches to preventing chronic disease.
Dr. Kaskel is also the founder and CEO of Holy Chiat, a fiber supplement.
